Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience

INTRODUCTION Lecanemab has demonstrated both safety and efficacy in clinical trials; however, routine clinical data are sparse. We contribute to the growing body of real‐world safety data, with a special focus on amyloid‐related imaging abnormalities (ARIA). METHODS We conducted a retrospective chart review of 146 patients treated with lecanemab according to appropriate‐use recommendations at a specialty memory center clinic. RESULTS Real‐world safety and efficacy data closely resemble published data in the Clarity‐AD trial. Thirty‐three patients (23%) discontinued treatment; all remaining patients completed at least 12 months of treatment. We observed a positive trend toward increasing ARIA edema/effusion (ARIA‐E) with increasing mean arterial pressure and a mean amyloid clearance of −90.6 at 18 months. DISCUSSION When used according to appropriate‐use recommendations, lecanemab is as safe as reported in the Clarity‐AD trial. Further investigation into real‐world data is necessary for a more complete evaluation of lecanemab's safety and efficacy.